204 related articles for article (PubMed ID: 16544979)
41. Lentiviral vectors for the treatment of Wiskott-Aldrich syndrome.
Nienhuis AW
Gene Ther; 2005 Apr; 12(7):555-6. PubMed ID: 18360950
[No Abstract] [Full Text] [Related]
42. Ten years of gene therapy for primary immune deficiencies.
Aiuti A; Roncarolo MG
Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
[TBL] [Abstract][Full Text] [Related]
43. Gene therapy for Wiskott-Aldrich Syndrome.
Bosticardo M; Ferrua F; Cavazzana M; Aiuti A
Curr Gene Ther; 2014; 14(6):413-21. PubMed ID: 25245089
[TBL] [Abstract][Full Text] [Related]
44. Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy.
Blundell MP; Bouma G; Calle Y; Jones GE; Kinnon C; Thrasher AJ
Mol Ther; 2008 May; 16(5):836-44. PubMed ID: 18388921
[TBL] [Abstract][Full Text] [Related]
45. The genotype of the original Wiskott phenotype.
Binder V; Albert MH; Kabus M; Bertone M; Meindl A; Belohradsky BH
N Engl J Med; 2006 Oct; 355(17):1790-3. PubMed ID: 17065640
[TBL] [Abstract][Full Text] [Related]
46. Wiskott-Aldrich Syndrome: a model for defective actin reorganization, cell trafficking and synapse formation.
Notarangelo LD; Ochs HD
Curr Opin Immunol; 2003 Oct; 15(5):585-91. PubMed ID: 14499269
[TBL] [Abstract][Full Text] [Related]
47. New insights into the biology of Wiskott-Aldrich syndrome (WAS).
Thrasher AJ
Hematology Am Soc Hematol Educ Program; 2009; ():132-8. PubMed ID: 20008191
[TBL] [Abstract][Full Text] [Related]
48. Stem-cell gene therapy for the Wiskott-Aldrich syndrome.
Boztug K; Schmidt M; Schwarzer A; Banerjee PP; Díez IA; Dewey RA; Böhm M; Nowrouzi A; Ball CR; Glimm H; Naundorf S; Kühlcke K; Blasczyk R; Kondratenko I; Maródi L; Orange JS; von Kalle C; Klein C
N Engl J Med; 2010 Nov; 363(20):1918-27. PubMed ID: 21067383
[TBL] [Abstract][Full Text] [Related]
49. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro.
Dewey RA; Avedillo Díez I; Ballmaier M; Filipovich A; Greil J; Güngör T; Happel C; Maschan A; Noyan F; Pannicke U; Schwarz K; Snapper S; Welte K; Klein C
Exp Hematol; 2006 Sep; 34(9):1161-9. PubMed ID: 16939809
[TBL] [Abstract][Full Text] [Related]
50. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes.
Zhang J; Shehabeldin A; da Cruz LA; Butler J; Somani AK; McGavin M; Kozieradzki I; dos Santos AO; Nagy A; Grinstein S; Penninger JM; Siminovitch KA
J Exp Med; 1999 Nov; 190(9):1329-42. PubMed ID: 10544204
[TBL] [Abstract][Full Text] [Related]
51. Genome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome.
Naseem A; Steinberg Z; Cavazza A
Front Immunol; 2022; 13():966084. PubMed ID: 36059471
[TBL] [Abstract][Full Text] [Related]
52. WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype.
Imai K; Nonoyama S; Ochs HD
Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):427-36. PubMed ID: 14612666
[TBL] [Abstract][Full Text] [Related]
53. WASP-WIP complex in the molecular pathogenesis of Wiskott-Aldrich syndrome.
Sasahara Y
Pediatr Int; 2016 Jan; 58(1):4-7. PubMed ID: 26331277
[TBL] [Abstract][Full Text] [Related]
54. Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells.
Benjelloun F; Garrigue A; Demerens-de Chappedelaine C; Soulas-Sprauel P; Malassis-Séris M; Stockholm D; Hauer J; Blondeau J; Rivière J; Lim A; Le Lorc'h M; Romana S; Brousse N; Pâques F; Galy A; Charneau P; Fischer A; de Villartay JP; Cavazzana-Calvo M
Mol Ther; 2008 Aug; 16(8):1490-9. PubMed ID: 18560421
[TBL] [Abstract][Full Text] [Related]
55. Wiskott-Aldrich syndrome.
Notarangelo LD; Miao CH; Ochs HD
Curr Opin Hematol; 2008 Jan; 15(1):30-6. PubMed ID: 18043243
[TBL] [Abstract][Full Text] [Related]
56. Clinical aspects and molecular analysis of Chinese patients with Wiskott-Aldrich syndrome in Taiwan.
Lee WI; Yang CY; Jaing TH; Huang JL; Chien YH; Chang KW
Int Arch Allergy Immunol; 2008; 145(1):15-23. PubMed ID: 17703096
[TBL] [Abstract][Full Text] [Related]
57. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome.
Candotti F
J Clin Immunol; 2018 Jan; 38(1):13-27. PubMed ID: 29086100
[TBL] [Abstract][Full Text] [Related]
58. Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome.
Mantovani J; Charrier S; Eckenberg R; Saurin W; Danos O; Perea J; Galy A
J Gene Med; 2009 Aug; 11(8):645-54. PubMed ID: 19455589
[TBL] [Abstract][Full Text] [Related]
59. Gene therapy for Wiskott-Aldrich syndrome: History, new vectors, future directions.
Ferrua F; Marangoni F; Aiuti A; Roncarolo MG
J Allergy Clin Immunol; 2020 Aug; 146(2):262-265. PubMed ID: 32623069
[No Abstract] [Full Text] [Related]
60. Phenotypic and genotypic correction of WASP gene mutation in Wiskott-Aldrich syndrome by unrelated cord blood stem cell transplantation.
Lee YH; Lim YJ; Shin SA; Song CH; Jo EK; Jung JA; Lee HB
J Korean Med Sci; 2009 Aug; 24(4):751-4. PubMed ID: 19654965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
